Antibody evasion and receptor binding of SARS-CoV-2 LP.8.1.1, NB.1.8.1, XFG, and related subvariants
- PMID: 41091599
- DOI: 10.1016/j.celrep.2025.116440
Antibody evasion and receptor binding of SARS-CoV-2 LP.8.1.1, NB.1.8.1, XFG, and related subvariants
Erratum in
-
Antibody evasion and receptor binding of SARS-CoV-2 LP.8.1.1, NB.1.8.1, XFG, and related subvariants.Cell Rep. 2025 Nov 24;44(12):116715. doi: 10.1016/j.celrep.2025.116715. Online ahead of print. Cell Rep. 2025. PMID: 41296568 No abstract available.
Abstract
SARS-CoV-2 continues to evolve, causing waves of infections. It is critical to understand the features of the virus that explain its growth advantages. Recently, SARS-CoV-2 Omicron JN.1 subvariants KP.3.1.1 and XEC were outcompeted by LP.8.1 and LP.8.1.1. Other subvariants, including LF.7.2.1 and MC.10.1, were also under monitoring. Subsequently, NB.1.8.1 and XFG became dominant. We found that serum neutralizing antibody titers against LP.8.1, LP.8.1.1, LF.7, LF.7.2.1, and MC.10.1 were similar to XEC in 40 adults, including KP.2 monovalent mRNA vaccine recipients. NB.1.8.1 and XFG were more evasive of serum neutralization than LP.8.1.1. Neutralization by 12 monoclonal antibodies (mAbs) revealed that LP.8.1 and XFG, MC.10.1 and NB.1.8.1, and LF.7.2.1 evade different mAb classes. Lastly, the receptor-binding affinity of LP.8.1 was the highest among the tested viruses. Unlike most prior SARS-CoV-2 sublineage evolutionary trajectories, receptor-binding affinity better explained the rise of LP.8.1, while expansion of NB.1.8.1 and XFG appears correlated with enhanced antibody evasion.
Keywords: COVID-19; CP: Immunology; CP: Microbiology; KP.2; LP.8.1; NB.1.8.1; SARS-CoV-2; XFG; mRNA vaccines; neutralizing antibodies.
Copyright © 2025 The Authors. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests D.D.H. co-founded TaiMed Biologics and RenBio, and he serves as a consultant for WuXi Biologics and Brii Biosciences and is a board director at Vicarious Surgical. A.G. served as a member of the scientific advisory board for Janssen Pharmaceuticals and has consulted and serves on a scientific advisory board for Sanofi Pasteur.
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
